Ocular Therapeutix (OCUL) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Ocular Therapeutix (OCUL) Reports In-Line Q4 EPS

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

February 28, 2022 4:01 PM EST

DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $12.2 Million, Representing Year-Over-Year Growth of 77%

Creating New Business Unit Focused on Optimizing the Commercial Opportunity for DEXTENZA in the Office Setting

Completed Enrollment in U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD; Data Anticipated in the Second Half of 2022

Conference Call to Discuss Fourth Quarter Results to be Held at 4:30 p.m. ET

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:... More